LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

LLY

821.04

-0.03%↓

UNH

516.91

+0.47%↑

JNJ

163.76

+0.38%↑

ABBV

205.38

+1.34%↑

NVO

69.36

-1.14%↓

Search

Boston Scientific Corp.

Închisă

SectorSănătate

99.39 -1.26

Rezumat

Modificarea prețului

24h

Curent

Minim

99.01

Maxim

99.5

Indicatori cheie

By Trading Economics

Venit

-138M

562M

Vânzări

352M

4.6B

P/E

Medie Sector

82.136

73.239

EPS

0.7

Marjă de profit

12.322

Angajați

53,000

EBITDA

-41M

1B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+19.72% upside

Dividende

By Dow Jones

Următoarele câștiguri

23 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-250M

152B

Deschiderea anterioară

100.65

Închiderea anterioară

99.39

Sentimentul știrilor

By Acuity

59%

41%

311 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Boston Scientific Corp. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 mar. 2025, 12:35 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5 feb. 2025, 12:23 UTC

Câștiguri

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

8 ian. 2025, 12:33 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific to Buy Rest of Bolt Medical for $443 Million

4 nov. 2024, 13:01 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific to Buy Medical-Technology Company Cortex

3 mar. 2025, 11:59 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3 mar. 2025, 11:58 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3 mar. 2025, 11:58 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5 feb. 2025, 21:33 UTC

Câștiguri

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 feb. 2025, 15:20 UTC

Câștiguri

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 feb. 2025, 11:39 UTC

Câștiguri

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5 feb. 2025, 11:39 UTC

Câștiguri

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5 feb. 2025, 11:38 UTC

Câștiguri

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5 feb. 2025, 11:38 UTC

Câștiguri

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5 feb. 2025, 11:37 UTC

Câștiguri

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5 feb. 2025, 11:37 UTC

Câștiguri

Boston Scientific 4Q Adj EPS 70c >BSX

5 feb. 2025, 11:37 UTC

Câștiguri

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5 feb. 2025, 11:37 UTC

Câștiguri

Boston Scientific 4Q Sales $4.56B >BSX

5 feb. 2025, 11:37 UTC

Câștiguri

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5 feb. 2025, 11:37 UTC

Câștiguri

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5 feb. 2025, 11:37 UTC

Câștiguri

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5 feb. 2025, 11:37 UTC

Câștiguri

Boston Scientific 4Q EPS 38c >BSX

8 ian. 2025, 12:10 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific Sees Deal More Dilutive on GAAP Basis >BSX

8 ian. 2025, 12:09 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific Sees Deal Slightly Dilutive to Adj EPS in 2025 >BSX

8 ian. 2025, 12:09 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific to Pay Up to Another $221M After Certain Regulatory Milestones >BSX

8 ian. 2025, 12:08 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific: Deal Includes Upfront Payment of About $443M for 74% Stake Not yet Owned >BSX

8 ian. 2025, 12:07 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific: Buyout to Further Co's Strategy to Address Coronary and Peripheral Disease >BSX

8 ian. 2025, 12:07 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific: Buyout to Expand Cardiovascular Portfolio With Complementary, Differentiated Calcium Modification Platform >BSX

8 ian. 2025, 12:00 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific Announces Agreement To Acquire Bolt Medical, Inc. >BSX

25 nov. 2024, 12:00 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific Announces Agreement To Acquire Intera Oncology(R) Inc. >BSX

15 nov. 2024, 13:43 UTC

Achiziții, Fuziuni, Preluări

Boston Scientific Closes Acquisition Of Axonics, Inc. >BSX AXNX

Comparație

Modificare preț

Boston Scientific Corp. Așteptări

Obiectiv de preț

By TipRanks

19.72% sus

Prognoză pe 12 luni

Medie 118.95 USD  19.72%

Maxim 135 USD

Minim 100 USD

În baza a 23 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBoston Scientific Corp. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

23 ratings

22

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

99.22 / 101Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

311 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.